$11.25
Value $102M
ICCC and UNH stock compared: price, dividend, valuation and results, from SEC filings.
$11.25
Value $102M
$349.91
Value $318B
ImmuCell (ICCC) has a market value of $102M and UnitedHealth (UNH) $318B. Over the last year, with dividends, ICCC moved +129.1% and UNH +12.1%. The P/E is 54.2 for ICCC and 20.0 for UNH. Dividend yield: ICCC none, UNH 2.59%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
ICCC$102M
UNH$318B
UNH is 3,121 times ICCC
Revenue, 12 months
ICCC$33M
UNH$450B
UNH is 13,540 times ICCC
Net income, 12 months
ICCC$1.9M
UNH$15.9B
UNH is 8,451 times ICCC
Operating margin
ICCC14.5%
UNH5.3%
9.2 points apart
ROIC
ICCC9.8%
UNH11.3%
1.5 points apart
P/E
ICCC54.2
UNH20.0
ICCC is 2.7 times UNH
Dividend yield
ICCC0.0%
UNH2.6%
2.6 points apart
5-year return
ICCC+24.2%
UNH-14.7%
38.9 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
ICCC+24.2%
UNH-14.7%
| Period | ICCCWith dividends | UNHWith dividends |
|---|---|---|
| 1 year since November 17, 2025 | +129.1%Price +129.1% | +12.1%Price +9.2% |
| 3 years since November 17, 2023 | +136.3%+33.2% a yearPrice +136.3% | -30.5%-11.4% a yearPrice -34.8% |
| 5 years since November 17, 2021 | +24.2%+4.4% a yearPrice +24.2% | -14.7%-3.1% a yearPrice -22.1% |
| 10 years since November 18, 2016 | +116.3%+8.0% a yearPrice +116.3% | +176.5%+10.7% a yearPrice +134.1% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
ICCCImmuCellUNHUnitedHealth
| Price | $11.25 | $349.91 |
|---|---|---|
| Market value | $102M | $318B |
| Enterprise value (EV) | $102M | $363B |
| P/E | 54.2 | 20.0 |
| P/E, 5-year median | – | 25.0 |
| P/B | 3.1 | 3.1 |
| EV/EBIT | 21.2 | 15.2 |
| Free cash flow yield | 5.3% | 7.2% |
| Revenue, 12 months | $33M | $450B |
|---|---|---|
| Net income, 12 months | $1.9M | $15.9B |
| Free cash flow, 12 months | $5.4M | $22.8B |
| Earnings per share, 12 months | $0.19 | $17.52 |
| Revenue growth, year on year | 4.3% | 11.8% |
| Revenue growth a year, past | +12.5%over 5 years | +11.7%over 5 years |
| EPS growth a year, past | – | -3.8%over 5 years |
| Gross margin | 40.8% | 88.3% |
|---|---|---|
| Operating margin | 14.5% | 5.3% |
| Net margin | 5.7% | 3.5% |
| ROIC | 9.8% | 11.3% |
| ROE | 6.3% | 15.5% |
| Cash | $7.9M | $28.5B |
|---|---|---|
| Total debt | $12M | $74.3B |
| Net debt / EBITDA | 0.0 | 1.6 |
| Interest cover | 12.2× | 6.2× |
| Dividend yield | – | 2.6% |
|---|---|---|
| Dividend per share, 12 months | – | $9.06 |
| Dividend growth a year, past | – | +12.6%over 5 years |
| Buyback yield | – | 1.8% |
| Shareholder yield | – | 4.3% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, UnitedHealth ($318B) is about 3,120.6 times ImmuCell ($102M), at today's prices.
Since November 18, 2016, ICCC's price moved +116.3% and UNH's +134.1%. With dividends: ICCC +116.3% (+8.0% a year), UNH +176.5% (+10.7% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for ImmuCell and 2.59% for UnitedHealth. Over the last twelve months they paid – and $9.06 per share.
At today's price, the P/E is 54.2 for ICCC and 20.0 for UNH. It is the share price over the last twelve months' earnings per share.
Over the last twelve months, the net margin was 5.7% for ImmuCell and 3.5% for UnitedHealth, and the operating margin 14.5% and 5.3%. Revenue was $33M and $450B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.